New Investigational Fertility Pill; Biden Wants Lower GLP-1 Prices; BVO to Be Banned

The investigational pill OXO-001 boosted pregnancy rates 10.6 percentage points higher than placebo in women who underwent assisted reproductive technology fertility treatment in a phase II trial, developer Oxolife announced.

There were clinically meaningful reductions in major atherogenic blood lipids after Roux-en-Y gastric bypass surgery that appeared to be independent of weight loss. (JAMA Surgery)

President Biden called on Novo Nordisk and Eli Lilly to slash the prices of their GLP-1 receptor agonists. (Reuters)

Upon reaching age 65, when most patients enroll in Medicare, quarterly out-of-pocket costs for type 2 diabetes drugs increased by an average of $23.04. (JAMA Network Open)

Compared with bisphosphonates, denosumab (Prolia, Xgeva) for osteoporosis was associated with a reduced risk of developing type 2 diabetes, all-cause mortality, and microvascular complications in a large global database. (Diabetes, Obesity and Metabolism)

Is testosterone being overprescribed in menopausal women? (The Guardian)

Turner Syndrome-associated diabetes has features of both type 1 and type 2, according to researchers in the Journal of Clinical Endocrinology & Metabolism.

The FDA plans to ban the use of brominated vegetable oil (BVO) in food and beverages by next month. BVO exposure may be toxic to the thyroid, the agency noted.

Please enable JavaScript to view the comments powered by Disqus.